In Focus channel feed – Endpoints News

In Focus channel feed

Bad trip: How culture conflict and a need for cash nearly broke Lykos

7 months ago

Recursion nears ‘moment of truth’ with first key data, kicking off 18-month flurry of readouts

8 months ago

Once one of immuno-oncology's next great hopes, CD47 faces final shots on goal

8 months ago

The obesity drug race is being fought on the manufacturing floor as GLP-1 rivals make plans to catch leaders

9 months ago

A teenager faced constant seizures. Could a drug developed just for him stop them?

9 months ago

Lykos’ pain is others’ gain as psychedelic biotechs take notes from adcomm vote

10 months ago

The Endpoints Slack interview: Saji Wickramasekara on where AI misses the mark — and what's next for Benchling

10 months ago

How two academic chemists turned San Diego startup Iambic into an AI force

10 months ago

BIO's new CEO takes a patriotic pivot to win back Congress, pushing industry to rethink China relationship

11 months ago

The Endpoints Slack interview: Siddhartha Mukherjee on the doctor-writer worldview, AI, and the future of cancer

12 months ago

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Last year

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Last year

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

Last year

With GIP, obesity research is at odds

Last year

The US could upend biopharma manufacturing. WuXi rivals have an opening

Last year

Female investors track progress, call for more women on boards and in leadership roles

Last year

WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down

Last year

Startups raised millions to in-license drugs to China. Then the model fell apart

Last year

Amylyx readies for make-or-break PhIII, looking to address uncertainty over controversial ALS drug

Last year

Failure, faith and $8 billion: How Lilly's amyloid conviction brought it to the brink of Alzheimer's approval

Last year

Once a scientific backwater, protein research attracts billion-dollar deals and high-profile publications

Last year

'Obesity plus': What’s next for GLP-1s?

Last year

In clash over science and national security, Chinese rival to Illumina struggles with US expansion

Last year

A sweeping form of search-and-replace editing has come for mRNA

Last year

First page Previous page 123 4 5 Next page Last page